Jeffrey Stewart
Expertise in
10
conditions

Dr. Jeffrey Stewart

Intensive Care Medicine
Mary Hitchcock Memorial Hospital
1 Medical Center Dr, 
Lebanon, NH 
Offers Telehealth
Expertise in
10
conditions
Mary Hitchcock Memorial Hospital
1 Medical Center Dr, 
Lebanon, NH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Stewart is an Intensive Care Medicine provider in Lebanon, New Hampshire. Dr. Stewart is highly rated in 10 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Acute Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease (COPD), and Interstitial Lung Disease.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Licenses
Critical Care Medicine in PA
Hospital Affiliations
Mary Hitchcock Memorial Hospital
Alice Peck Day Memorial Hospital
New London Hospital
Concord Hospital- Laconia
Cheshire Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Mary Hitchcock Memorial Hospital
1 Medical Center Dr, Lebanon, NH 03756

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-1)
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Drug
Study Drug: Treprostinil
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Enrollment Status: Terminated
Publish Date: November 24, 2023
Intervention Type: Drug
Study Drug: Inhaled treprostinil solution
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Enrollment Status: Terminated
Publish Date: July 27, 2023
Intervention Type: Combination product
Study Drug: INOpulse
Study Phase: Phase 3
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study
A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis or Sarcoidosis on Long Term Oxygen Therapy Followed by an Optional Open-Label Long Term Extension Safety Study
Enrollment Status: Completed
Publish Date: August 10, 2022
Intervention Type: Combination product
Study Drug: iNO
Study Phase: Phase 2
View 4 Less Clinical Trials

9 Total Publications

Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.
Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.
Journal: Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
Published: February 22, 2022
Similar Doctors
Expertise in
15
conditions
Dr. David Feller
Intensive Care Medicine
Expertise in
15
conditions
Dr. David Feller
Intensive Care Medicine

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (0.2 miles away)
603-650-5533
Languages Spoken:
English
See accepted insurances

David Feller is an Intensive Care Medicine provider in Lebanon, New Hampshire. Dr. Feller is highly rated in 15 conditions, according to our data. His top areas of expertise are Pleural Effusion, Lymphofollicular Hyperplasia, Lung Nodules, Endoscopy, and Advanced Bronchoscopy.

Expertise in
8
conditions
Dr. Graham Atkins
Intensive Care Medicine
Expertise in
8
conditions
Dr. Graham Atkins
Intensive Care Medicine

Mary Hitchcock Memorial Hospital

1 Medical Center Dr, 
Lebanon, NH 
 (0.2 miles away)
603-650-5533
Languages Spoken:
English
See accepted insurances

Graham Atkins is an Intensive Care Medicine provider in Lebanon, New Hampshire. Dr. Atkins is highly rated in 8 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Lung Metastases, Acute Interstitial Pneumonia, and Interstitial Lung Disease.

Expertise in
9
conditions
Dr. Mitsuo Matsuoka
Intensive Care Medicine
Expertise in
9
conditions
Dr. Mitsuo Matsuoka
Intensive Care Medicine

White River Junction Veterans Affairs Medical Center

215 N Main St, 
White River Junction, VT 
 (3.0 miles away)
802-295-9363
Languages Spoken:
English
See accepted insurances

Mitsuo Matsuoka is an Intensive Care Medicine provider in White River Junction, Vermont. Dr. Matsuoka is highly rated in 9 conditions, according to our data. His top areas of expertise are Cystic Fibrosis, Secondary Immunodeficiency (SID), Chronic Obstructive Pulmonary Disease (COPD), and Newborn Jaundice.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stewart's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 29 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile